
    
      This is a Phase 1, randomized, double-blind, placebo-controlled study designed to evaluate
      the safety, tolerability, and pharmacokinetics of LB-102 in healthy subjects. The study will
      consist of two parts: Part A - Single Ascending Dose and Part B - Multiple Ascending Doses.
      There will be 5 cohorts in Part A and 3 Cohorts in Part B of this study. Each cohort consists
      of 8 subjects, with 6 subjects assigned to LB-102 and 2 subjects assigned to placebo.

      In Parts A and B, eligible subjects will be randomized on Day 1 (pre-dose) to placebo (n=2)
      or LB-102 (n=6). Eligible subjects will receive 1 dose on Day 1 (Part A) or 13 doses on Days
      1-7 (Part B) of placebo or LB-102.
    
  